Skip to main content
Erschienen in: Journal of Gastrointestinal Cancer 2/2015

01.06.2015 | Original Research

Concomitant Chemoradiotherapy with Cisplatin Plus 5-Fluorouracil for Anal Squamous Cell Carcinoma

verfasst von: Hend Ahmed El-Hadaad, Hanan Ahmed Wahba, Sameh Roshdy

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Objective

The objective of this study was to evaluate the results of combined chemoradiotherapy using 5-fluorouracil and cisplatin with radiation in treatment of anal squamous cell carcinoma in terms of local control, survival, and toxicity.

Patients and Methods

This study included 32 patients with histologically confirmed locally advanced anal squamous cell carcinoma (T1–4 with any N). They received chemotherapy consisted of 5-fluorouracil 1000 mg/m2/day on the first 5 and last 5 days of RT, cisplatin 75 mg/m2 on days 2 and 30. External beam RT consisted of 45Gy/f/25 sessions/5 sessions per week. A boost of 9Gy/5 sessions was given to those who developed complete or partial response.

Results

Median age was 55 years with female to male ratio 2.2:1. Fifty-six percent of them had ECOGPS of 1; moderately differentiated pathology was the most common one (53 %). Thirteen patients (40.6 %) presented with N0 and 56 % presented with T2. None of the patients died of acute complications and none developed grade 4 toxicity. Non-hematological complications were more common than hematological ones. Dermatitis was the most common toxicity (59.3 %) than diarrhea and neurologic one (40.7 %). Anemia was the most frequent hematological adverse event (37.5 %). Complete response was reported in 81.2 %. After median follow-up of 25 months, local recurrence was observed in five patients (15.6 %) as the following: three in the anal canal and two in the inguinal lymph nodes. Three patients (9.4 %) developed distant metastasis (two in the liver and one in the lung), while one patient (3 %) had both local and distant metastases. Three-year overall survival rate (OS) was 81.3 %, while 3-year progression-free survival (PFS) rate was 72 %, and colostomy-free survival was 90 %.

Conclusion

Concomitant chemoradiotherapy of 5-fluorouracil and cisplatin with radiotherapy is a highly effective and well-tolerated treatment of anal cancer. But further studies with larger number of patients are needed to support the indication to treat anal cancer using this regimen.
Literatur
1.
2.
Zurück zum Zitat Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Oraganization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997;15:2024–49. Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Oraganization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997;15:2024–49.
3.
Zurück zum Zitat Anonymous. Epidermoid anal cancer: results from the UKCCCR randomized trial of radiotherapy alone versus radiotherapy, 5- fluorouracil, and mitomycin .UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee Cancer Res Lancet 1996; 348:1049–54. Anonymous. Epidermoid anal cancer: results from the UKCCCR randomized trial of radiotherapy alone versus radiotherapy, 5- fluorouracil, and mitomycin .UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee Cancer Res Lancet 1996; 348:1049–54.
4.
Zurück zum Zitat Falm M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized lntergroup study. J Clin Oncal. 1996;14:2527–39. Falm M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized lntergroup study. J Clin Oncal. 1996;14:2527–39.
5.
Zurück zum Zitat Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340:1137–43.CrossRefPubMed Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340:1137–43.CrossRefPubMed
6.
Zurück zum Zitat Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin based radiotherapy and chemotherapy for locally advanced cervical cancer.[Erratum appears in N Eng J Med 1999 Aug 26; 341(9):708]. N Engl J Med. 1999; 340:1144–1153. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin based radiotherapy and chemotherapy for locally advanced cervical cancer.[Erratum appears in N Eng J Med 1999 Aug 26; 341(9):708]. N Engl J Med. 1999; 340:1144–1153.
7.
Zurück zum Zitat Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation,and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. [Erratum appears in N Engl J Med 1999 Au26; 341(9):708]. N Engl J Med. 1999; 340:1154–1161. Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation,and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. [Erratum appears in N Engl J Med 1999 Au26; 341(9):708]. N Engl J Med. 1999; 340:1154–1161.
8.
Zurück zum Zitat Peiffert D, Giovannini M, Ducreux M, et al. Highdose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal carcinoma: final results of a phase II study. Ann Oncol. 2001;12(3):397–404.CrossRefPubMed Peiffert D, Giovannini M, Ducreux M, et al. Highdose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal carcinoma: final results of a phase II study. Ann Oncol. 2001;12(3):397–404.CrossRefPubMed
9.
Zurück zum Zitat Meropol NJ, Niedzwiecki D, Shank B, et al. Proceedings of the ASCO Gastrointestinal Symposium. Combined-modality therapy of poor prognosis anal canal carcinoma: a phase II study of cancer and leukemia group B (CALGB). In: Alexandria, VA: American Society of Clinical Oncology; 2005. Abstract 238. Meropol NJ, Niedzwiecki D, Shank B, et al. Proceedings of the ASCO Gastrointestinal Symposium. Combined-modality therapy of poor prognosis anal canal carcinoma: a phase II study of cancer and leukemia group B (CALGB). In: Alexandria, VA: American Society of Clinical Oncology; 2005. Abstract 238.
11.
Zurück zum Zitat Kim KH, Chang JS, Keum KC, et al. Chemoradiotherapy in squamous cell carcinoma of the anal canal: a single institution experience. Radiat Oncol J. 2013;31(1):25–33.CrossRefPubMedCentralPubMed Kim KH, Chang JS, Keum KC, et al. Chemoradiotherapy in squamous cell carcinoma of the anal canal: a single institution experience. Radiat Oncol J. 2013;31(1):25–33.CrossRefPubMedCentralPubMed
12.
Zurück zum Zitat John M, Flam M, Berkey B, et al. Proceedings of the American Society of Clinical Oncology 5-Year results and analyses of a phase III randomized RTOG/ECOG chemoradiation protocol for anal cancer. Alexandria, VA: American Society of Clinical Oncology; 1998. Abstract 989. John M, Flam M, Berkey B, et al. Proceedings of the American Society of Clinical Oncology 5-Year results and analyses of a phase III randomized RTOG/ECOG chemoradiation protocol for anal cancer. Alexandria, VA: American Society of Clinical Oncology; 1998. Abstract 989.
13.
Zurück zum Zitat Deniaud-Alexandre E, Touboul E, Tiret E, et al. Epidermoid carcinoma of anal canal treated with radiation therapy and concomitant chemotherapy (5-florouracil and cisplatin). Cancer Radiother. 2006;10(8):572–82.CrossRefPubMed Deniaud-Alexandre E, Touboul E, Tiret E, et al. Epidermoid carcinoma of anal canal treated with radiation therapy and concomitant chemotherapy (5-florouracil and cisplatin). Cancer Radiother. 2006;10(8):572–82.CrossRefPubMed
14.
Zurück zum Zitat Cho BC, Ahn JB, Seong J, et al. Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients. BMC Cancer. 2008;8:8.CrossRefPubMedCentralPubMed Cho BC, Ahn JB, Seong J, et al. Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients. BMC Cancer. 2008;8:8.CrossRefPubMedCentralPubMed
15.
Zurück zum Zitat Koerber SA, Slynko A, Haefner M, et al. Efficacy and toxicity of chemoradiation in patients with anal cancer—a retrospective analysis. Radiat Oncol J. 2014;9:113.CrossRef Koerber SA, Slynko A, Haefner M, et al. Efficacy and toxicity of chemoradiation in patients with anal cancer—a retrospective analysis. Radiat Oncol J. 2014;9:113.CrossRef
16.
Zurück zum Zitat Doci R, Zucali R. La monica G et al. Primary chemoradiation therapy with fluorouracil and cisplatin for cancer of the anus: results in 35 consecutive patients. J Clin Oncol. 1996;14:3121–5.PubMed Doci R, Zucali R. La monica G et al. Primary chemoradiation therapy with fluorouracil and cisplatin for cancer of the anus: results in 35 consecutive patients. J Clin Oncol. 1996;14:3121–5.PubMed
17.
Zurück zum Zitat Hung A, Crane C, Delclos M, et al. Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index. Cancer. 2003;97:1195–202.CrossRefPubMed Hung A, Crane C, Delclos M, et al. Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index. Cancer. 2003;97:1195–202.CrossRefPubMed
18.
Zurück zum Zitat Gerald JP, Ayzac L, Hun D, et al. Treatment of anal canal carcinoma with high dose radiation therapy and concomitant fluorouracil-cisplatinum. Long-term results in 95 patients. Radiother Oncol. 1998;46:249–56.CrossRef Gerald JP, Ayzac L, Hun D, et al. Treatment of anal canal carcinoma with high dose radiation therapy and concomitant fluorouracil-cisplatinum. Long-term results in 95 patients. Radiother Oncol. 1998;46:249–56.CrossRef
19.
Zurück zum Zitat Olivatto LO, Carbal V, Rosa A, et al. Mitomycin-C- or cisplatin-based chemoradiotherapy for anal canal carcinoma: long –term results. Int J Radiat Oncol Biol Phys. 2011;79(2):490–5.CrossRefPubMed Olivatto LO, Carbal V, Rosa A, et al. Mitomycin-C- or cisplatin-based chemoradiotherapy for anal canal carcinoma: long –term results. Int J Radiat Oncol Biol Phys. 2011;79(2):490–5.CrossRefPubMed
20.
Zurück zum Zitat James RD, Glynne-Jones R, Meadows HM, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACTII):a randomized, phase 3, open-label,2 × 2 factorial trial. Lancet Oncol. 2013;14(6):516–24.CrossRefPubMed James RD, Glynne-Jones R, Meadows HM, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACTII):a randomized, phase 3, open-label,2 × 2 factorial trial. Lancet Oncol. 2013;14(6):516–24.CrossRefPubMed
21.
Zurück zum Zitat Gunderson LL, Winter KA, Ajani JA, et al. Long-term update of US GI intergroup RTOG 98–11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol. 2012;30(35):4344–51.CrossRefPubMedCentralPubMed Gunderson LL, Winter KA, Ajani JA, et al. Long-term update of US GI intergroup RTOG 98–11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol. 2012;30(35):4344–51.CrossRefPubMedCentralPubMed
22.
Zurück zum Zitat Olivatto LO, Vieira FM, Pereira BV, et al. Phase I study of cetuximab in combination with 5-fluorouracil, cisplatin and radiotherapy in patients with locally advanced anal canal carcinoma. Cancer. 2013;119(16):2973–80.CrossRefPubMed Olivatto LO, Vieira FM, Pereira BV, et al. Phase I study of cetuximab in combination with 5-fluorouracil, cisplatin and radiotherapy in patients with locally advanced anal canal carcinoma. Cancer. 2013;119(16):2973–80.CrossRefPubMed
23.
Zurück zum Zitat Pintor MP, Northover JM, Nicholls RJ. Squamous cell carcinoma of the anus at one hospital from 1948–1984. Br J Surg. 1989;76:806–10.CrossRefPubMed Pintor MP, Northover JM, Nicholls RJ. Squamous cell carcinoma of the anus at one hospital from 1948–1984. Br J Surg. 1989;76:806–10.CrossRefPubMed
24.
Zurück zum Zitat Tomaszewski JM, Link E, Leong T, et al. Twenty-five-year experience with radical chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys. 2012;83(2):552–8.CrossRefPubMed Tomaszewski JM, Link E, Leong T, et al. Twenty-five-year experience with radical chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys. 2012;83(2):552–8.CrossRefPubMed
Metadaten
Titel
Concomitant Chemoradiotherapy with Cisplatin Plus 5-Fluorouracil for Anal Squamous Cell Carcinoma
verfasst von
Hend Ahmed El-Hadaad
Hanan Ahmed Wahba
Sameh Roshdy
Publikationsdatum
01.06.2015
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Cancer / Ausgabe 2/2015
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-015-9707-2

Weitere Artikel der Ausgabe 2/2015

Journal of Gastrointestinal Cancer 2/2015 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.